With the emergence of new virus variants, limited data are available on the impact of SARS-CoV-2 Omicron infection on surgery outcomes in cancer patients who have been widely vaccinated. This study aimed to determine whether undergoing hepatectomy poses a higher risk of postoperative complications for liver cancer patients who have had mild Omicron infection before surgery. A propensity-matched cohort study was conducted at a tertiary liver center from 8 October 2022 to 13 January 2023. In total, 238 liver cancer patients who underwent hepatectomy were included, with 57 (23.9%) recovering from preoperative SARS-CoV-2 Omicron infection and 190 (79.8%) receiving COVID-19 vaccination. Pre- and post-matching, there was no significant difference in the occurrence of postoperative outcomes between preoperative COVID-19 recovered patients and COVID-19 negative patients. Multivariate logistic regression showed that the COVID-19 status was not associated with postoperative major pulmonary and cardiac complications. However, preexisting comorbidities (odds ratio [OR], 4.645; 95% confidence interval [CI], 1.295–16.667), laparotomy (OR, 10.572; 95% CI, 1.220–91.585), and COVID-19 unvaccinated (OR, 5.408; 95% CI, 1.489–19.633) had increased odds of major complications related to SARS-CoV-2 infection. In conclusion, liver cancer patients who have recovered from preoperative COVID-19 do not face an increased risk of postoperative complications.
随着新型冠状病毒变异株的出现，关于广泛接种疫苗的癌症患者感染SARS-CoV-2奥密克戎毒株对手术结局影响的现有数据有限。本研究旨在探讨术前曾感染轻症奥密克戎毒株的肝癌患者接受肝切除术是否会导致更高的术后并发症风险。某三级肝脏中心于2022年10月8日至2023年1月13日开展了一项倾向性匹配队列研究，共纳入238例接受肝切除术的肝癌患者，其中57例（23.9%）为术前SARS-CoV-2奥密克戎感染康复者，190例（79.8%）曾接种新冠疫苗。匹配前后分析显示，术前新冠康复患者与新冠阴性患者的术后结局发生率均无显著差异。多因素逻辑回归分析表明，新冠感染状态与术后重大心肺并发症无显著关联。然而，既存合并症（比值比[OR]为4.645；95%置信区间[CI]为1.295–16.667）、开腹手术（OR为10.572；95%CI为1.220–91.585）以及未接种新冠疫苗（OR为5.408；95%CI为1.489–19.633）均会显著增加SARS-CoV-2感染相关重大并发症的发生风险。研究结论表明，术前新冠康复的肝癌患者并未面临更高的术后并发症风险。
肿瘤(癌症)患者之家